Compare TSEM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSEM | VTRS |
|---|---|---|
| Founded | 1993 | 1961 |
| Country | Israel | United States |
| Employees | N/A | 30000 |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9B | 21.0B |
| IPO Year | 1996 | 2019 |
| Metric | TSEM | VTRS |
|---|---|---|
| Price | $146.39 | $20.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $275.21 | $21.00 |
| AVG Volume (30 Days) | 3.2M | ★ 9.0M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.32% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $27.80 | $3.53 |
| Revenue Next Year | $39.15 | $3.69 |
| P/E Ratio | $66.16 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.30 | $10.15 |
| 52 Week High | $319.94 | $21.20 |
| Indicator | TSEM | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 71.15 |
| Support Level | $129.95 | $16.02 |
| Resistance Level | $196.51 | N/A |
| Average True Range (ATR) | 13.36 | 0.58 |
| MACD | 0.33 | 0.17 |
| Stochastic Oscillator | 24.01 | 87.62 |
Tower Semiconductor Ltd is a pure-play specialty foundry that manufactures semiconductors. As a pure-play foundry, it focuses on producing integrated circuits (ICs) based on the design specifications of customers. The company's line of integrated circuits is incorporated into markets, including consumer electronics, personal computers, communications, automotive, and industrial and medical device products. It produces ICs alongside wholly-owned subsidiaries through fabrication facilities located in Japan. The company has a geographical presence in the USA, Japan, Asia (other than Japan), and Europe.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.